Compare GRFS & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | INSP |
|---|---|---|
| Founded | 1940 | 2007 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 2.2B |
| IPO Year | N/A | 2018 |
| Metric | GRFS | INSP |
|---|---|---|
| Price | $7.86 | $56.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $10.15 | ★ $101.07 |
| AVG Volume (30 Days) | 711.5K | ★ 1.1M |
| Earning Date | 07-28-2022 | 05-04-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | N/A | ★ 4.89 |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | $5.33 | $8.44 |
| Revenue Next Year | $6.50 | $8.60 |
| P/E Ratio | $18.67 | ★ $11.52 |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $6.19 | $53.11 |
| 52 Week High | $11.14 | $172.95 |
| Indicator | GRFS | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 31.46 | 34.26 |
| Support Level | $7.64 | $53.11 |
| Resistance Level | $9.11 | $84.26 |
| Average True Range (ATR) | 0.23 | 2.89 |
| MACD | -0.08 | 0.23 |
| Stochastic Oscillator | 7.04 | 14.61 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.